Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITHIODOTE vs FINGOLIMOD
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nithiodote (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobinemia, which competitively binds cyanide, while sodium thiosulfate serves as a sulfur donor for the enzyme rhodanese, converting cyanide to thiocyanate, which is renally excreted.
Sphingosine 1-phosphate receptor modulator; acts as a functional antagonist by downregulating S1P receptors on lymphocytes, preventing their egress from lymph nodes and reducing peripheral lymphocyte count.
FDA-approved for the treatment of acute cyanide poisoning,Off-label: May be used for cyanide poisoning due to smoke inhalation or certain chemical exposures
Relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease,Off-label: chronic inflammatory demyelinating polyneuropathy (CIDP)
NITHIODOTE (sodium nitrite) 10 mg/kg IV push over 2 minutes, followed by sodium thiosulfate 50 mg/kg IV push over 10 minutes. Repeat half doses after 30 minutes if needed.
0.5 mg orally once daily
Terminal elimination half-life: 2.5–3 hours in adults with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is 6–9 days due to enteropathic recirculation and high Vd; clinical context: steady state reached in 1–2 months, duration of immunosuppression persists for weeks after discontinuation.
Sodium nitrite is partially metabolized to nitric oxide and other metabolites; sodium thiosulfate is primarily excreted unchanged in urine, with minor metabolism by rhodanese in the liver and kidneys.
Primarily metabolized by CYP4F2 via ω-hydroxylation; minor contributions from CYP2D6, CYP2E1, CYP3A4, and CYP4F12. Also undergoes reversible phosphorylation to active metabolite fingolimod-phosphate.
Primarily renal as unchanged drug and metabolites; biliary/fecal excretion minimal (<5%).
Primarily via biliary/fecal excretion (81% of dose recovered in feces as metabolites); renal excretion accounts for <2.5% of unchanged drug.
Approximately 90% bound to albumin.
>99.7% bound to human serum albumin; minor binding to lipoproteins.
0.35 L/kg, indicating moderate tissue distribution.
Vd approximately 1000 L/kg (17,000 L); extensive distribution into tissues, particularly lung, blood cells, and CNS.
Oral: 60–80% (first-pass metabolism); IV: 100%.
Oral bioavailability is approximately 93% following a single 5 mg dose; food does not significantly affect absorption.
No dose adjustment required for mild-moderate renal impairment (GFR >30 m L/min). For severe renal impairment (GFR <30 m L/min), consider reducing sodium thiosulfate dose by 50% and monitoring serum thiocyanate levels.
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). Not studied in severe renal impairment (GFR <30 m L/min); use with caution.
No dose adjustment required for mild hepatic impairment (Child-Pugh A). For moderate-severe (Child-Pugh B/C), use with caution; consider reducing sodium nitrite dose by 50% due to increased methemoglobinemia risk.
Child-Pugh Class A or B: No dose adjustment. Child-Pugh Class C: Contraindicated.
Children: Sodium nitrite 0.15-0.33 m L/kg of 3% solution (4.5-10 mg/kg) IV push over 2 minutes, followed by sodium thiosulfate 1.65 m L/kg of 25% solution (412.5 mg/kg) IV push over 10 minutes. Repeat half doses if symptoms persist.
For patients 10 years and older weighing >40 kg: 0.5 mg orally once daily. For patients <10 years or ≤40 kg: Not recommended.
Geriatric patients: Use weight-based dosing (same as adult). Start with lower doses (e.g., sodium nitrite 5 mg/kg) due to increased risk of hypotension and methemoglobinemia. Monitor vital signs frequently.
No specific dose adjustment; monitor for bradycardia and atrioventricular block due to age-related conduction system changes. Caution in patients ≥65 years due to limited data.
None
Risk of serious infections; cases of fatal herpes infections (e.g., varicella zoster) reported. Requires baseline VZV serology and vaccination if negative.
May cause severe hypotension, especially in children,Risk of methemoglobinemia with excessive sodium nitrite,Use caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, as hemolysis may occur,Monitor methemoglobin levels, blood pressure, and oxygen saturation during therapy,Sodium thiosulfate may cause hypocalcemia in high doses
Bradyarrhythmia and AV block (monitor for 6 hours after first dose), increased infection risk (especially herpes viruses), macular edema (ophthalmologic exam at baseline and 3-4 months after initiation), progressive multifocal leukoencephalopathy (PML), posterior reversible encephalopathy syndrome (PRES), severe exacerbation of MS after discontinuation, respiratory effects (decline in FEV1 and DLCO), liver injury, fetal risk, blood pressure effects (hypertension), and risk of basal cell carcinoma.
Hypersensitivity to any component of the product,Children under 6 months of age (relative contraindication due to increased risk of hypotension and methemoglobinemia)
Patients with recent myocardial infarction (within 6 months), unstable angina, stroke, transient ischemic attack, decompensated heart failure, or history of Mobitz type II second-degree or third-degree AV block or sick sinus syndrome (unless pacemaker in place), severe active infections, and hypersensitivity to fingolimod or any of its excipients.
No known food interactions. Avoid alcohol as it may impair liver function and worsen acidosis.
Grapefruit juice and Seville oranges may increase drug levels; avoid consumption.
FDA Pregnancy Category C. First trimester: Limited human data, animal studies show fetal malformations at high doses. Second and third trimesters: Potential risk of fetal methemoglobinemia and hemolytic anemia due to methylene blue component; avoid near term due to risk of neonatal methemoglobinemia.
FDA Pregnancy Category C. Based on animal studies, fingolimod is associated with increased risk of fetal malformations, including persistent truncus arteriosus and ventricular septal defects, particularly during the first trimester. Human data are limited, but case reports suggest potential fetal harm. Contraindicated in pregnancy. Women of childbearing potential must use effective contraception during treatment and for 2 months after discontinuation.
No human data; methylene blue is excreted in breast milk with an M/P ratio of approximately 0.7. Potential for infant methemoglobinemia; caution advised. Consider withholding breastfeeding for 4-6 hours after maternal dose.
Fingolimod is excreted in human breast milk. The milk-to-plasma ratio (M/P) is approximately 2:1. Based on a typical maternal dose, the estimated infant exposure is about 0.2-0.4% of the maternal weight-adjusted dose. Due to potential for serious adverse effects (immunosuppression, bradycardia), breastfeeding is not recommended during fingolimod therapy.
Standard dosing (1 mg/kg IV) used in pregnancy; consider lower dose (0.5-1 mg/kg) if severe anemia or G6PD deficiency. No routine dose adjustment, but monitor for maternal hypotension and fetal bradycardia.
No specific dose adjustment guidelines exist for fingolimod during pregnancy due to teratogenicity. Pregnancy is a contraindication; discontinue fingolimod before conception or as soon as pregnancy is detected. Pharmacokinetic studies in pregnancy are lacking; no evidence of altered metabolism requiring dose adjustment if used inadvertently.
NITHIODOTE (sodium nitrite and sodium thiosulfate) is indicated for acute cyanide poisoning. Administer intravenously as soon as possible after exposure. Monitor methemoglobin levels; do not exceed 20% methemoglobinemia. Use with caution in patients with G6PD deficiency due to risk of hemolytic anemia. Sodium nitrite induces methemoglobinemia which can impair oxygen delivery; ensure adequate ventilation. Sodium thiosulfate is generally safer and can be given separately.
First-dose monitoring required for 6 hours due to bradycardia risk; obtain baseline ECG, CBC, LFTs. Avoid live vaccines; screen for latent infections. Rebound disease activity may occur upon discontinuation; taper not needed but monitor closely.
This medication is only used in hospital settings for cyanide poisoning.,It is given through an IV line as soon as possible after exposure.,You may experience symptoms of low oxygen such as headache, confusion, or blue skin due to methemoglobin formation.,Tell your doctor if you have a history of G6PD deficiency, anemia, or breathing problems.,Follow-up blood tests will be needed to monitor your oxygen levels and blood counts.
Your heart rate will be monitored for 6 hours after your first dose.,Do not stop fingolimod without consulting your doctor; stopping can cause severe return of MS symptoms.,Avoid grapefruit juice and Seville oranges.,Report any signs of infection, slow heart rate, or visual changes immediately.,Use effective contraception during treatment and for 2 months after stopping.
No interactions on record
"Fingolimod, a sphingosine 1-phosphate receptor modulator used for multiple sclerosis, can inhibit the metabolism of lorcaserin, a serotonin 2C receptor agonist for weight management. This occurs via fingolimod's moderate inhibition of CYP2D6, the primary enzyme responsible for lorcaserin's oxidative deamination. Increased lorcaserin exposure may heighten the risk of serotonin-related adverse effects, including nausea, headache, and potentially life-threatening serotonin syndrome."
"Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, impairs B-cell receptor signaling and reduces B-cell and T-cell function, leading to immunosuppression. Fingolimod, a sphingosine-1-phosphate receptor modulator, sequesters lymphocytes in lymph nodes, further decreasing peripheral lymphocyte counts. Coadministration may result in profound immunosuppression, increasing the risk of serious infections, including opportunistic infections and viral reactivation, as well as potential impairment of vaccine responses."
"Dexamethasone, a potent corticosteroid with profound immunosuppressive and anti-inflammatory effects, may potentiate the immunosuppressive actions of fingolimod, a sphingosine-1-phosphate receptor modulator used in multiple sclerosis. This additive immunosuppression increases the risk of opportunistic infections, including viral reactivation (e.g., herpes zoster) and serious bacterial infections. Clinical outcomes may range from prolonged infections to life-threatening sepsis, particularly in patients receiving high-dose or prolonged dexamethasone therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITHIODOTE vs FINGOLIMOD, answered by our medical review team.
NITHIODOTE is a Cyanide Antidote that works by Nithiodote (sodium nitrite and sodium thiosulfate) is a cyanide antidote. Sodium nitrite induces methemoglobinemia, which competitively binds cyanide, while sodium thiosulfate serves as a sulfur donor for the enzyme rhodanese, converting cyanide to thiocyanate, which is renally excreted.. FINGOLIMOD is a Sphingosine 1-Phosphate Receptor Modulator that works by Sphingosine 1-phosphate receptor modulator; acts as a functional antagonist by downregulating S1P receptors on lymphocytes, preventing their egress from lymph nodes and reducing peripheral lymphocyte count.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITHIODOTE and FINGOLIMOD depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITHIODOTE is: NITHIODOTE (sodium nitrite) 10 mg/kg IV push over 2 minutes, followed by sodium thiosulfate 50 mg/kg IV push over 10 minutes. Repeat half doses after 30 minutes if needed.. The standard adult dose of FINGOLIMOD is: 0.5 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITHIODOTE and FINGOLIMOD in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITHIODOTE is classified as Category C. FDA Pregnancy Category C. First trimester: Limited human data, animal studies show fetal malformations at high doses. Second and third trimesters: Potential risk of fetal methemogl. FINGOLIMOD is classified as Category C. FDA Pregnancy Category C. Based on animal studies, fingolimod is associated with increased risk of fetal malformations, including persistent truncus arteriosus and ventricular sept. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.